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Abstract
Current evidence suggests an analgesic role for the spinal cord action of general anesthetics;
however, the cellular population and intracellular mechanisms underlying anti-visceral pain by
general anesthetics still remain unclear. It is known that visceral nociceptive signals are transmited
via post-synaptic dorsal column (PSDC) and spinothalamic tract (STT) neuronal pathways and that
the PSDC pathway plays a major role in visceral nociception. Animal studies report that persistent
changes including nociception-associated molecular expression (e.g. neurokinin-1 (NK-1)
receptors) and activation of signal transduction cascades (such as the protein kinase A [PKA]-c-
AMP-responsive element binding [CREB] cascade)-in spinal PSDC neurons are observed following
visceral pain stimulation. The clinical practice of interruption of the spinal PSDC pathway in patients
with cancer pain further supports a role of this group of neurons in the development and
maintenance of visceral pain. We propose the hypothesis that general anesthetics might affect
critical molecular targets such as NK-1 and glutamate receptors, as well as intracellular signaling by
CaM kinase II, protein kinase C (PKC), PKA, and MAP kinase cascades in PSDC neurons, which
contribute to the neurotransmission of visceral pain signaling. This would help elucidate the
mechanism of antivisceral nociception by general anesthetics at the cellular and molecular levels
and aid in development of novel therapeutic strategies to improve clinical management of visceral
pain.
Introduction
Visceral pain is the most common sign of acute and
chronic gastrointestinal, pelvic, genitourinary, and other
internal solid-organ diseases. When visceral structures are
stretched, compressed, inflamed, or distended, a poorly
localized noxious visceral feeling is reported. As one of the
most common causes of long-term suffering and persist-
ent disability, this represents a frequent reason for
patients to seek medical treatment. Despite multiple ther-
apeutic approaches, the medical community still faces a
significant challenge to relieve acute and chronic visceral
pain effectively, especially in cancer patients with pain.
On the other hand, as practical anesthesiology extends
itself into peri-operative pain treatment, the anesthesiolo-
gist's expertise in the management of intra-operative vis-
ceral pain and intractable or cancer-related visceral pain is
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apeutic procedures, such as gastrointestinal and genitouri-
nary endoscopies are associated with visceral organs,
which can cause acute visceral nociception and may
require general anesthetic administration including infu-
sion of propofol or inhalation of sevoflurane. However,
little is known regarding the spinal mechanisms underly-
ing the inhibition of visceral nociception by general anes-
thetics.
It has been demonstrated that the spinal cord is one of the
critical working targets of general anesthetics [2,3]. A
study indicates that general anesthetics, such as propofol
and isoflurane, may affect different cellular populations
in the spinal cord to produce analgesia and immobility
[4]. Several ascending tracts originating from the spinal
cord such as the spinothalamic, spinohypothalamic,
spinoreticular, spinoparabrachial, spinomesencephalic,
spinosolitary, and spinolimbic tracts have been shown to
play roles in transmission of noxious somatic and visceral
information [5]. Additionally, recent investigations from
bench and bedside by our group suggest that a critical vis-
ceral nociceptive pathway originates from PSDC neurons
located in the central area of the spinal cord [6-8]. Inter-
ruption of the PSDC pathway using different surgical
approaches relieves intractable visceral pain in cancer
patients [9-15]. Therefore, based on current laboratory
and clinical findings, we hypothesize that general anes-
thetics exert an inhibitory effect on visceral nociception
via the PSDC pathway. Investigation of inhibition of the
PSDC pathway by general anesthetics will identify a neu-
robiological mechanism of general anesthetic action and
should help in the development of novel therapeutic strat-
egies for visceral pain management. This review will sum-
marize the effects of general anesthetics in blocking
visceral pain with a focus on the role of the spinal PSDC
pathway.
Role of the PSDC pathway and PSDC neurons in the 
transmission of visceral nociception
Traditionally, the STT is believed to be the most important
nociceptive pathway, while the dorsal column (DC) sys-
tem is usually considered to be involved in signaling
information concerning innocuous stimuli [16]. How-
ever, several clinical and experimental studies have pro-
vided compelling evidence that the DC pathway plays a
critical role in relaying visceral nociceptive information
[6-8,17-19]. In clinical settings, transection of the lateral
column of the spinal cord does not provide effective vis-
ceral pain relief, while the interruption of DC leads to
considerable relief of intractable visceral pain in cancer
patients [6,7]. Electrophysiological experiments in labora-
tory animals showed that a lesion of the DC or DC nuclei
in medullar oblongata significantly diminished the
increased activity of thalamic ventroposteriolateral nuclei
evoked by noxious visceral stimuli [20,21]. Behavioral
studies in mice demonstrated that a high cervical midline
punctate myelotomy apparently decreased the somatic
responses to the intraperitoneal injection of acetic acid
[22]. The reduction of exploratory activity present after the
capsaicin injection could be prevented by ipsilateral dor-
sal rhizotomy or a contralateral lesion of the lateral funic-
ulus, but was not affected by a DC lesion. In contrast, a
bilateral DC lesion made prior to noxious colon stimula-
tion counteracted the decrease in exploratory activity
observed in naïve animals, and this effect could last up to
180 days following the interruption of the DC pathway
[23]. These findings confirmed an important role of the
PSDC pathway in visceral nociceptive neurotransmission.
The DC pathway is composed of input of branches of pri-
mary afferent fibers, some of which project directly to the
DC nuclei, and input of axons of PSDC neurons (Figure
1). PSDC neurons are located in the nucleus proprius and
in the vicinity of the central canal in the spinal gray matter
and project to the gracile and cuneate DC nuclei [24]. The
activation of PSDC neurons by noxious visceral stimuli in
rats was demonstrated in recent experiments [25-28]. Fol-
lowing noxious ureter stimulation, a higher percentage of
retrogradely labeled PSDC neurons showed the expres-
sion of c-fos protein than of STT neurons, while no signif-
icant difference in c-fos expression in these two
populations of neurons was detected after intradermal
capsaicin injection [26]. Intraspinal application of mor-
phine or the AMPA receptor antagonist, CNQX, to block
neurotransmission at the spinal cord level prevents the
activation of neurons in the gracile nucleus induced by
noxious colonic distention [27]. This suggested a great
contribution of PSDC neurons than of STT neurons in
transmitting noxious visceral stimuli.
Activation of signal transduction pathways in PSDC 
neurons in response to visceral stimuli
Noxious visceral stimulation, such as intracolonic injec-
tion of mustard oil or capsaicin, produced an enhanced
responsiveness of spinal nociceptive neurons involved in
triggering the activation of a number of neurotransmis-
sion molecules. An increased expression of neurokinin
NK1 receptors in PSDC neurons was demonstrated after
colonic inflammation or bladder irritation [25,29]. NK1
receptor expression is upregulated in the dorsal horn and
in PSDC neurons after visceral stimuli [29]. Intrathecally
applied NK1 antagonists significantly reduce abdominal
muscle contractions induced by colon inflammation [30].
Visceral primary afferents are known to be rich in neu-
ropeptides, such as substance P (SP), and a significant def-
icit in visceral nociceptive perception was observed in
studies of SP-receptor (NK1) knockout mice [31,32].
These results indicate that NK1 receptors in PSDC neu-
rons play a critical role in the transmission of visceralPage 2 of 8
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application of an AMPA receptor antagonist, CNQX,
could block the response of PSDC neurons to colonic dis-
tension, indicating that AMPA receptor activation was
involved in nociceptive transmission by PSDC neurons
[27].
It has been reported that the second messenger system
conveys extracellular nociceptive signals from the plasma
membrane into the nucleus of neurons in animal models
of pain [33-35]. The activation of nociceptive receptors
causes a large influx of extracellular calcium into nocicep-
tive neurons; the increased calcium influx, in turn, acti-
vates multiple intracellular protein kinase cascades, such
as CaM kinase II, PKA, and PKC [36-40]. Our group dem-
onstrated the intracellular cascade in PSDC neurons medi-
ated by PKA in a visceral pain model in rats with the
intracolonic injection of mustard oil [41,42]. We found
that intracolonic injection of mustard oil significantly
induced the expression of PKA kinase protein, as well as
CREB, in the lumbosacral spinal cord and in pre-labeled
PSDC neurons. An intrathecal infusion of the PKA inhib-
itor, H 89, significantly blocked the visceral stimulation-
induced phosphorylation of CREB protein in the spinal
cord. This suggests that the PKA-mediated signal transduc-
tion cascade may contribute to visceral nociceptive trans-
mission in PSDC neurons. It has been revealed that
phosphorylation of glutamate receptors is regulated by
PKA at serine/theonine residues, which are involved in
central sensitization [36,37,43]. NR1 subunits of NMDA
receptor and GluR1 subunits of AMPA receptors are phos-
phorylated by PKA. An AMPA receptor antagonist, CNQX,
could block the response of PSDC neurons to colonic dis-
tension in rats [8]. To combine the finding of the
increased expression of PKA in PSDC neurons, we could
suggest that a possible role for PKA in regulation of AMPA
receptor activity in PSDC neurons during visceral painful
states. Additionally, it has been demonstrated that sex
steroid hormones, such as estrogen, increased the activity
of spinal NMDA receptors via PKA-mediated phosphor-
ylation of NR1 subunits in an animal visceral pain model
[44]. Another important role for the activation of PKA in
PSDC neurons is that PKA may mediate painful stimula-
tion-elicited gene expression through its regulation of
transcription factors, such as c-fos and CREB
[33,35,40,45]. Increased phosphorylation of CREB
through the activated PKA was involved in CGRP-induced
NK1 receptor gene expression in spinal neurons [46]. It
also suggests that activation of PKA in PSDC neurons
might increase CREB-induced the expression of NK1
receptor and contribute to the sensitization of PSDC neu-
rons (Figure 2).
Another important component of secondary messenger
system, PKC is widely reported to play a role in long term
potentiation of spinal nociceptive neurons. Recently, our
group demonstrated the phosphorylation of γ-PKC kinase
in signaling visceral nociceptive transmission in PSDC
neurons [47]. Interestingly, another group investigated
the expression of γ-PKC isoform in spinal cord and gracile
nucleus and they found that approximately 90% of γ-
PKC-positive neurons in gracile nucleus and 60% in dor-
sal horn co-expressed GluR2/3 subunits of AMPA receptor
[48]. It may link to a role for phosphorylated PKC kinases
in AMPA receptor regulation in PSDC system during vis-
ceral pain states.
A family of multi-functional kinases, the mitogen-acti-
vated protein kinases (MAPKs) is critical intracellular sig-
nal mediators to regulate neuronal development and
differentiation, as well as responses to extracellular stress
and inflammation [49-51]. The activation of p38 MAPK
Dorsal column pathway of visceral pain transmissionFigure 1
Dorsal column pathway of visceral pain transmission. 
Adapted from Nauta HJ, et al. Surgical interruption of a mid-
line dorsal column visceral pain pathway. J Neurosurg, 
86:538–542, 1997. The dorsal column pathway is composed 
of branches of primary afferent fibers, some of which project 
directly to the dorsal column nuclei, and of the axons of 
postsynaptic dorsal column neurons. Pelvic viscera nocicep-
tive input activates the postsynaptic dorsal column neurons 
of the spinal cord and is relayed to higher centers. PSDC 
neurons receiving pelvic visceral input send their axons in the 
midline of the dorsal column to synapse in the nucleus graci-
lis. Then, the pathway crosses the midline in the lower brain-
stem to ascend to the ventral posterolateral nucleus of the 
thalamus. PSDC (postsynaptic dorsal column); VPL (ventral 
posterolateral), DRG (dorsal root ganglion).Page 3 of 8
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neuropathic pain [52,53]. Spinal extracellular signaling-
regulated kinase-1 and -2 (ERK1/2) activation was
reported to play a specific role in maintaining prolonged
referred visceral hyperalgesia in adult mice [54]. Periph-
eral injection of hUcn 2, a corticotropin releasing factor 2
(CRF2) receptor agonist, blunts colorectal distension
(CRD) induced visceral pain in an ERK 1/2 activity-
dependent manner in spinal neurons [55]. However, the
role of ERK activity involved in signaling visceral nocicep-
tion in PSDC neurons is still unclear. Recently, phospho-
rylation of ERK was reported to occur in NK1 receptor-
expressing neurons in laminae III-IV of rats following nox-
ious stimulation [56]. Additionally, other critical neuro-
transmitters, such as NMDA and non NMDA glutamate
receptors, NK1 receptors and brain-derived neurotrophic
factor (BDNF) receptor were reported to be coupled to
phosphorylated ERK in the dorsal horn neurons [57-59].
Combining these studies, we suggest that phosphoryla-
tion of MAP kinases might play an important role in sign-
Neurochemical signal transduction pathways in the PSDC neurons in response to visceral stimuliFig re 2
Neurochemical signal transduction pathways in the PSDC neurons in response to visceral stimuli. The activation 
of nociceptive receptors causes a large influx of calcium into the nociceptive neurons and the increased calcium influx, in turn, 
activates multiple intracellular protein kinases. PKA regulates the phosphorylation of glutamate receptors. Another important 
role for the activation of PKA in PSDC neurons is its effect on painful stimulation-elicited gene expression through mediation 
of transcription factors, such as c-fos and CREB. PKA in PSDC neurons might increase the expression of NK1 receptors 
through mediation of CREB and contribute to the sensitization of PSDC neurons.Page 4 of 8
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mechanism may be involved in the regulation of activity
of glutamate and NK1 receptors in PSDC neurons [60].
These studies help to better understand the molecular sig-
nal transduction pathways in PSDC neurons under vis-
ceral pain conditions (Figure 2). Other neuronal signaling
transduction pathways relaying the information involved
in PSDC neurons following visceral nociceptive stimula-
tion may deserve more investigation. These signaling
transduction pathways which relay the visceral signals in
PSDC neurons may serve as a development of drug target
for clinical visceral pain treatment and open the possibil-
ity of replacing surgical neuroablative approaches by
pharmacological agents.
Antinociceptive effect of general anesthetics on spinal 
neurons
Most volatile anesthetics can induce unconsciousness,
suppress autonomic responsiveness and block motor
responses to noxious stimulation. Several studies have
revealed that the minimum alveolar concentration (MAC)
of volatile anesthetics, which is required to prevent the
spontaneous mobility to nociceptive stimuli in 50% of
subjects, is critically dependent on spinal-cord regulation
[61-63]. The depression of motor response to noxious
stimulation may be caused by immobilization and anti-
nociceptive effects at the spinal-cord level [64]. An antino-
ciceptive effect of halothane was observed since decreased
extracellular activity of single wide-dynamic-range dorsal
horn neurons was recorded in animals subjected to nox-
ious-stimuli after inhalation of halothane [65]. Further-
more, the inhibitory effect of halothane was blocked by
bicuculline, a γ-aminobutyric acid type A receptor antago-
nist [65]. This indicates that the antinociceptive effect of
volatile anesthetics may involve γ-aminobutyric acid-
mediated (GABAergic) transmission in the spinal dorsal
horn. Wakai et al. also reported an antinociceptive effect
of isoflurane in lamina II (substantia gelatinosa) of the
spinal cord dorsal horn, which is considered to be an
important structure for pain transmission [66]. They
reported that isoflurane application significantly aug-
ments GABA-mediated inhibitory effects since it further
reduces excitability of dorsal horn neurons [66]. Cuellar et
al. compared the effects of halothane and isoflurane on
lumbar dorsal horn neuronal windup and excitability
[67]. They found that windup was significantly greater fol-
lowing isoflurane administration than after halothane
anesthesia at the level of 1.2 MAC since the initial noc-
cieptive C-fiber-mediated response was suppressed much
more by using isoflurane. Volatile anesthetics may also
affect the sensory functions mediated by spinal N-methyl-
D-aspartate (NMDA)- and NK-1- receptors. A study
showed that windup is gradually increased in spinal neu-
rons in response to repeated stimulation of C-fibers. The
data also revealed temporal summation of NMDA- and
NK-1- receptor-mediated slow cumulative depolariza-
tions of spinal neurons evoked by primary nociceptive
afferent input. Other studies suggested that sevoflurane,
another inhalation anesthetic, produced robust inhibitory
effects on spinal GABAergic neurons in an in vitro experi-
ment using isolated spinal cords [68]. Sevoflurane also
modulates potassium channel conductance and depresses
sensory neuronal responses mediated by glutamate recep-
tors following noxious stimuli [69,70]. Although the spi-
nal cord is believed to be the predominant target site
where volatile anesthetics produce immobility during
anesthetic procedures, the precisely targeted cellular pop-
ulation and specific neurobiological mechanisms remain
less investigated in the setting of visceral pain states.
As one of the commonly used intravenous anesthetics in
current clinical practice, propofol is widely applied in vis-
ceral procedures due to its analgesic action. An in vitro
experiment showed that propofol potentiated a depres-
sant effect of opioid at a low concentration (about 0.15
μM) [71]. At clinically relevant concentration ranges
(from 0.5 to 1 μM), it can produce a modest reduction of
dorsal root-ventral root reflexes [72]. Matute et al.
reported, in an in vitro preparation, that propofol had an
inhibitory effect on spinal nociceptive transmission when
giving at anesthetic concentrations in a hemisected rat spi-
nal cord [68]. Using a multimodal electrophysiological
assessment, Kammer et al. reported that both propofol
and sevoflurane targeted preferentially the spinal cord at
subanesthetic levels of dosage [73]. Nishiyama et al.
reported that intrathecal propofol has analgesic effects on
inflammation-induced nociception without sedative
effect in rats [74]. Another in vivo experiment indicated
that propofol had analgesic effects by depressing spinal
sensitization [75]. Several clinical reports also found that
propofol could reduce both H-reflexes and F-waves at sub-
anesthetic concentrations, indicating that spinal effects of
propofol could be observed [73,76]. Based on these stud-
ies from laboratories and clinics, the spinal antinocicep-
tive effects of propofol can be confirmed.
It has been reported that several amino acid receptors are
involved in the spinal antinociceptive action of propofol.
Propofol works as a modulator of both GABAA and glycine
receptors in the brain and spinal cord; these receptors play
crucial roles in spinal antinociception [77,78]. Facilitation
of GABAA and glycine receptors by propofol at the spinal-
cord level might contribute to analgesia based on several
studies [79-81]. Shimizu et al. reported that propofol
enhanced GABAA receptor-mediated presynaptic inhibi-
tion at primary afferent terminals in the human spinal
cord [80]. Nadeson et al. reported that intrathecal injec-
tion of a GABAA antagonist, dicentrine, inhibited the anal-
gesic action of propofol in a dose-dependent mannerPage 5 of 8
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antinociceptive mechanism of propofol in the spinal
cord. To investigate the interaction between propofol and
spinal opioid receptors, Nadeson's group found that a δ
opioid receptor antagonist, Naltrexone, inhibited the
analgesic action of propofol at the lumbosacral level of
the cord [81]. Feng et al. reported that propofol potenti-
ated the depressant effect of alfentanil in isolated neonatal
rat spinal cord and blocked Naloxone-precipitated hyper-
responsiveness [82]. Additionally, spinal NMDA receptors
were reported to be involved in the antinociceptive action
of propofol. Xu et al. reported that intrathecal administra-
tion of an NMDA receptor agonist inhibited the antinoci-
ceptive effect of propofol; in contrast, an NMDA receptor
antagonist enhanced the antinociceptive action of propo-
fol [83]. These studies demonstrated that propofol has a
synergistic action with several nociceptive transmission
cascades including amino acid and opioid systems in the
spinal cord.
Potential molecular mechanisms of general anesthetics in 
inhibiting visceral pain
General anesthetics produce analgesia by acting on the
spinal cord. But the precise mechanisms underlying vis-
ceral pain inhibiting by general anesthetics remain
unclear. Recently, Kim et al. reported that neurons in the
ventral spinal cord were more depressed by isoflurane,
halothane, and propofol than neurons in the dorsal cord.
It may suggest the possibility that PSDC neurons may be
more vulnerably depressed by general anesthetics than
neurons in superficial dorsal horn, since PSDC neurons
are predominantly located in the vicinity of central canal
in the spinal gray matter [84]. As summarized above, vol-
atile anesthetics may act on spinal NMDA, AMPA, NK1
receptor, which are proved to be involved in the signaling
transduction of PSDC neurons in visceral nociception.
Therefore, we may suggest that volatile anesthetics possi-
bly exert inhibitory effects on visceral pain transmission
via those receptors in PSDC neurons. Similarly, com-
monly used intravenous anesthetic, propofol, may possi-
bly exert the antinociception to visceral stimuli via the
inhibition of NMDA receptors in PSDC neurons. GABAA
and Glycine receptors are the important targeting sites of
inhalational and intravenous anesthetics. However,
whether GABAA and Glycine receptors are involved in sig-
nal transduction in PSDC neurons in visceral nociception
remain to be determined. Additionally, it has been
reported that isoflurane or propofol may influence vari-
ous signaling transduction pathways such as PKC, CaMK,
ERK, etc in hypoxic or normal cortex neurons [85-88].
However, few studies have been done to investigate the
changes of signaling transduction pathways in spinal
nociceptive neurons during general anesthesia. How gen-
eral anesthetics affect the intracellular signaling transduc-
tion process in response to visceral pain in PSDC neurons
remain to be investigated. Investigation of nociceptive sig-
naling mechanisms of PSDC neurons involved in applica-
tion of general anesthesia will advance our knowledge of
clinical application of general anesthetics and help to
identify new molecular targets for developing novel anal-
gesic agents to manage visceral pain.
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